PMID- 20179240
OWN - NLM
STAT- MEDLINE
DCOM- 20100520
LR  - 20220330
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Linking)
VI  - 16
IP  - 5
DP  - 2010 Mar 1
TI  - New strategies in kidney cancer: therapeutic advances through understanding the 
      molecular basis of response and resistance.
PG  - 1348-54
LID - 10.1158/1078-0432.CCR-09-2273 [doi]
AB  - The emergence of viable therapeutic strategies in metastatic renal cell carcinoma 
      has invigorated translational and clinical research in this disease. Building 
      upon the clinical activity observed with inhibition of vascular endothelial 
      growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways, novel 
      strategies are being investigated to extend existing clinical benefits. 
      Preclinical study has identified potential molecular mechanisms of response and 
      resistance, providing a rational basis for biomarker development as well as 
      sequential and combination therapy strategies. Several treatment strategies have 
      emerged that are in the early phases of clinical testing. Further clinical and 
      translational research is needed to validate initial hypotheses and translate 
      observations into novel treatment strategies.
FAU - Rini, Brian I
AU  - Rini BI
AD  - Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 
      Glickman Urologic and Kidney Institute, Cleveland, Ohio 44195, USA. 
      rinib2@ccf.org
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100223
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/genetics
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/genetics
MH  - Translational Research, Biomedical
RF  - 54
EDAT- 2010/02/25 06:00
MHDA- 2010/05/21 06:00
CRDT- 2010/02/25 06:00
PHST- 2010/02/25 06:00 [entrez]
PHST- 2010/02/25 06:00 [pubmed]
PHST- 2010/05/21 06:00 [medline]
AID - 1078-0432.CCR-09-2273 [pii]
AID - 10.1158/1078-0432.CCR-09-2273 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2010 Mar 1;16(5):1348-54. doi: 10.1158/1078-0432.CCR-09-2273. 
      Epub 2010 Feb 23.